Macular oedema
Drug safety update
August 2017: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
NICE Guidance
See drug specific guidance below
Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch or central retinal vein occlusion and for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy. It is for specialist use only and is prescribed according to NICE guidance.
Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies. It is for specialist use only and is prescribed according to NICE guidance.
Other drugs used for the treatment of macular oedema include aflibercept, faricimab and ranibizumab according to NICE guidance.